| 翻訳と辞書 |
| Galmed Pharmaceuticals Ltd. ： ウィキペディア英語版 |
Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol,〔(【引用サイトリンク】url=http://www.marketwatch.com/story/galmed-pharmaceuticals-announces-us-fda-approval-of-fast-track-designation-of-aramchol-for-the-treatment-of-nash-2014-09-23 )〕 a novel, once-daily, oral therapy for treating liver diseases〔(【引用サイトリンク】url=http://www.news-medical.net/news/20140929/Galmed-Pharmaceuticals-purchases-EndoPAT-devices-accessories-from-Itamar-Medical.aspx )〕 utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates (FABACs). Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis (NASH),〔(【引用サイトリンク】url=http://www.benzinga.com/analyst-ratings/analyst-color/14/09/4872426/update-mlv-co-reiterates-on-galmed-pharmaceuticals-ltd-a )〕 a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance.〔(【引用サイトリンク】url=http://www.biospace.com/News/galmed-pharmaceuticals-completes-analysis-of-a/356363 )〕〔(【引用サイトリンク】url=http://topics.nytimes.com/top/news/business/companies/galmed-pharmaceuticals-ltd/ )〕
Galmed Pharmaceuticals, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, Galmed’s business has been operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABACs and NASH.〔(【引用サイトリンク】url=http://www.sec.gov/Archives/edgar/data/1595353/000114420414006610/v367324_f1.htm )〕
==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Galmed Pharmaceuticals Ltd.」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|